<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415724</url>
  </required_header>
  <id_info>
    <org_study_id>Shreya singh</org_study_id>
    <nct_id>NCT03415724</nct_id>
  </id_info>
  <brief_title>Comparison of Anesthetic Efficacy of Dexmedetomidine and Epinephrine With Lidocaine in Irreversible Pulpitis</brief_title>
  <official_title>Comparison of Anesthetic Efficacy of Dexmedetomidine and Epinephrine in Combination With 2% Lidocaine for Inferior Alveolar Nerve Block in Patients With Irreversible Pulpitis: A Prospective, Double Blinded, Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Dental Sciences Rohtak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Dental Sciences Rohtak</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to determine and compare the anaesthetic efficacy of dexmedetomidine and&#xD;
      epinephrine in combination with 2% lidocaine for inferior nerve block in patients with&#xD;
      irreversible pulpitis. Study will be conducted in Post Graduate Institute of Dental Sciences,&#xD;
      Rohtak in department of Conservative Dentistry &amp; Endodontics. Vital mature permanent&#xD;
      mandibular molars with radiographically exposed dentinal caries and with signs of&#xD;
      irreversible pulpitis will be included in the study. The patients will be randomly allocated&#xD;
      into two control and two experimental groups and nerve block will be given according to&#xD;
      standard protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIMS AND OBJECTIVES:&#xD;
&#xD;
      To evaluate the efficacy of conventional inferior alveolar nerve block in mandibular molars&#xD;
      with symptomatic irreversible pulpitis with injection dexmedetomidine plus injection&#xD;
      lignocaine and compare it with injection lignocaine plus adrenaline.&#xD;
&#xD;
      MATERIALS AND METHODS - Study subjects will be recruited from OPD of Department of&#xD;
      conservative dentistry and endodontics, PGIDS, Rohtak.&#xD;
&#xD;
      METHODOLOGY- Prior to treatment, a thorough clinical and radiological examination will be&#xD;
      carried out and a thorough history will be taken.&#xD;
&#xD;
      Clinical procedure:&#xD;
&#xD;
      Mature mandibular permanent molars exhibiting deep caries involving pulp radiographically&#xD;
      will be chosen for the study. The teeth will be evaluated by periapical radiographs,&#xD;
      periodontal probing, percussion test, and vitality assessment with thermal test and electric&#xD;
      pulp test; teeth determined to have irreversible pulpitis will be included and with&#xD;
      reversible pulpitis will be excluded. All periapical radiographs will be exposed by using&#xD;
      constant kVP, mA, and exposure time (70 KVP, 8 mA, and 0.8 sec.) with a Rinn paralleling&#xD;
      device.&#xD;
&#xD;
      Study groups:&#xD;
&#xD;
      The subjects will be randomly assigned to 2 EXPERIMENTAL AND 2 CONTROL groups. CONTROL GROUP&#xD;
      1 - The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of&#xD;
      2% inj lignocaine with adrenaline 1:80000.&#xD;
&#xD;
      CONTROL GROUP 2 - The study subjects will receive conventional inferior alveolar nerve block&#xD;
      with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.&#xD;
&#xD;
      EXPERIMENTAL GROUP 1 - conventional inferior alveolar nerve block with1.8 ml of injection&#xD;
      lignocaine plus injection dexmedetomidine 1micromol/ ml.&#xD;
&#xD;
      EXPERIMENTAL GROUP 2 - conventional inferior alveolar nerve block with3.6 ml of injection&#xD;
      lignocaine plus injection dexmedetomidine 1micromol/ ml.&#xD;
&#xD;
        -  Patients will be explained the treatment procedure and use of pain scales.&#xD;
&#xD;
        -  Patients will mark their pretreatment pain on a 170-mm HP VAS&#xD;
&#xD;
        -  The area of injection will be dried by using sterile gauze, and topical anesthesia of&#xD;
           20% benzocaine (Mucopain; ICPA, Mumbai, India) will be applied by using sterile&#xD;
           cotton-tip applicator for 60 seconds.&#xD;
&#xD;
        -  The solution will be injected via a 5-mL disposable syringe (pricon, jodhpur, India)&#xD;
           with a 24-gauge needle .&#xD;
&#xD;
        -  The anterior border of the mandibular ramus will be palpated and coronoid notch located.&#xD;
&#xD;
        -  The needle will be inserted on an imaginary line drawn from coronoid notch to the&#xD;
           pterygomandibular raphe, 2 mm above the occlusal plane of mandibular molars.&#xD;
&#xD;
        -  The barrel of the syringe will be in the opposite corner of the mouth, between the&#xD;
           mandibular premolars.&#xD;
&#xD;
        -  The needle will be inserted until bony resistance felt. After reaching the target area,&#xD;
           aspiration will be performed, and the solution will be deposited with a rate of 1&#xD;
           ml/min. No anaesthetic solution will be deposited during needle insertion and placement.&#xD;
&#xD;
      Heft-parker visual analogue scale (Heft &amp; Parker 1984), with 170-millimetre line marked with&#xD;
      various terms describing the levels of pain, will be used. The millimetre marks will be&#xD;
      removed from the scale, and the scale will be divided into 4 categories:&#xD;
&#xD;
        -  'no pain' corresponding to 0 mm;&#xD;
&#xD;
        -  'faint, weak or mild' pain corresponding to 1-54 mm;&#xD;
&#xD;
        -  'moderate' pain corresponding to 55-114 mm; and&#xD;
&#xD;
        -  severe pain corresponding above 114 mm and included 'strong, intense and maximum&#xD;
           possible' pain.&#xD;
&#xD;
             -  After 15 minutes, each patient will be asked whether his or her lip is numb.&#xD;
&#xD;
             -  If profound lip numbness is not recorded, the block will be considered&#xD;
                unsuccessful, and the patients will be excluded from the study.&#xD;
&#xD;
             -  A conventional access opening will be initiated after isolation with a rubber dam.&#xD;
                Patients will be instructed to raise their hand if any pain felt during the&#xD;
                procedure.&#xD;
&#xD;
             -  In case of pain during the treatment, the procedure will be stopped, and patients&#xD;
                will be asked to rate the pain on HP VAS.&#xD;
&#xD;
             -  The extent of access preparation and/or instrumentation will be recorded as&#xD;
&#xD;
        -  within dentin,&#xD;
&#xD;
        -  within pulpal space,&#xD;
&#xD;
        -  and instrumentation of canals. â€¢ Success will be defined as no pain or weak/mild pain&#xD;
           during endodontic access preparation and instrumentation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pain intensity</measure>
    <time_frame>The root canal treatment will be completed in two sittings and the second sitting will be provided after 3-4 days.The time frame of the study is estimated to be about 6 months</time_frame>
    <description>After giving inferior alveolar nerve block as per the standard protocol, conventional access opening will be initiated after isolation with a rubber dam. Patients will be instructed to raise their hand if any pain felt during the procedure and rate the pain on heft parker VAS scale.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Irreversible Pulpitis</condition>
  <arm_group>
    <arm_group_label>1.8 ml Lignocaine plus adrenaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study subjects will receive conventional inferior alveolar nerve block with 1.8 ml of 2% inj lignocaine with adrenaline 1:80000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.6 ml Lignocaine plus adrenaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study subjects will receive conventional inferior alveolar nerve block with 3.6 ml of 2% inj lignocaine with adrenaline 1:80000.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.8 ml Lignocaine plus dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional inferior alveolar nerve block with1.8 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.6 ml Lignocaine plus dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional inferior alveolar nerve block with3.6 ml of injection lignocaine plus injection dexmedetomidiene 1micromol/ ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inferior alveolar nerve block</intervention_name>
    <description>Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars</description>
    <arm_group_label>1.8 ml Lignocaine plus adrenaline</arm_group_label>
    <arm_group_label>1.8 ml Lignocaine plus dexmedetomidine</arm_group_label>
    <arm_group_label>3.6 ml Lignocaine plus adrenaline</arm_group_label>
    <arm_group_label>3.6 ml Lignocaine plus dexmedetomidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-50 years of age.&#xD;
&#xD;
          -  Patient willing to participate in the study.&#xD;
&#xD;
          -  Mature permanent mandibular first and second molars exhibiting signs of symptomatic&#xD;
             irreversible pulpitis as assessed by history, cold and electric pulp tests.&#xD;
&#xD;
          -  Absence of periapical lesions on radiographic examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient not ready to participate in the study voluntarily&#xD;
&#xD;
          -  Clinical history or electrocardiographic evidence of heart block, Ischaemic heart&#xD;
             disease&#xD;
&#xD;
          -  Asthma, Sleep apnoea syndrome.&#xD;
&#xD;
          -  Impaired liver, renal or mental function.&#xD;
&#xD;
          -  Alcohol consumption in excess of 28 units per week.&#xD;
&#xD;
          -  Chronic sedative and analgesic user and those having known allergy to study drugs&#xD;
&#xD;
          -  Patients with severe periodontal disease.&#xD;
&#xD;
          -  Patients unable to return for recall appointments&#xD;
&#xD;
          -  Signs or symptoms of external /internal resorption, furcation or periapical&#xD;
             radiolucency, swelling, or sinus tract.&#xD;
&#xD;
          -  Negative response to cold and electric pulp tests.&#xD;
&#xD;
          -  Antibiotic or analgesic intake within past 24 hours before treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shreya singh</last_name>
    <phone>9896326782</phone>
    <email>shreya.redhu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>shweta mittal</last_name>
    <phone>9255596960</phone>
    <email>shwetagoelendo@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Post Graduate Institute of Dental Sciences</name>
      <address>
        <city>Rohtak</city>
        <state>Haryana</state>
        <zip>124001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>December 29, 2017</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 31, 2018</last_update_submitted>
  <last_update_submitted_qc>January 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

